Results 121 to 130 of about 153,414 (353)

Early‐Stage Entrepreneurial Creativity: A Qualitative Study

Canadian Journal of Administrative Sciences / Revue Canadienne des Sciences de l'Administration, EarlyView.
ABSTRACT The creative process has long sparked debate over which types of relationships fuel it most effectively. Taking an interpretive interactionist perspective, we carry out a qualitative study of 30 technology entrepreneurs and 11 members of their “inner circle,” uncovering how friends and family serve a critical role in the creative process ...
Jessica Ruth Lenore Good
wiley   +1 more source

Changes in the Profitability-Growth Relation and the Implications for the Accrual Anomaly

, 2013
Meng Li
openalex   +1 more source

LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development

Cell, 2001
Y. Gong, R. Slee, N. Fukai, G. Rawadi, S. Roman-Roman, A. Reginato, Hongwei Wang, T. Cundy, F. Glorieux, D. Lev, M. Zacharin, K. Oexle, J. Marcelino, W. Suwairi, S. Heeger, G. Sabatakos, S. Apte, W. Adkins, J. Allgrove, M. Arslan‐Kirchner, J. Batch, P. Beighton, G. Black, R. Boles, L. Boon, C. Borrone, H. Brunner, G. Carle, B. Dallapiccola, A. Paepe, Barbara Floege, Melissa Lees Halfhide, B. Hall, R. Hennekam, T. Hirose, A. Jans, H. Jüppner, C. Kim, K. Keppler-Noreuil, A. Kohlschuetter, D. Lacombe, M. Lambert, E. Lemyre, T. Letteboer, L. Peltonen, R. Ramesar, M. Romanengo, H. Somer, E. Steichen‐Gersdorf, B. Steinmann, Beth Sullivan, A. Superti-Furga, W. Swoboda, M. V. D. Boogaard, W. Hul, M. Vikkula, M. Votruba, B. Zabel, Teresa Garcia, R. Baron, B. Olsen, M. Warman   +61 more
semanticscholar   +1 more source

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Clinical Pharmacology &Therapeutics, EarlyView.
We present model‐informed selection of the recommended dose for expansion (RDE) of investigational oral ATR inhibitor tuvusertib, by integrating clinical pharmacokinetics (PK), pharmacodynamics (PD), and safety data from DDRiver Solid Tumors 301 trial Part A1 (NCT04170153).
Jatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann, Timothy A. Yap, Ruth Plummer, Anthony W. Tolcher, Johann S. de Bono, Ioannis Gounaris, Zoltan Szucs, Astrid Zimmermann, Irina Kareva, Jayaprakasam Bolleddula, Annick Seithel‐Keuth, Giuseppe Locatelli, Marta Enderlin, Christine Hicking, Anup Zutshi, Wei Gao, Rainer Strotmann, Lisa Benincosa, Karthik Venkatakrishnan   +20 more
wiley   +1 more source

Errors in Estimating Accruals: Implications for Empirical Research

, 2002
C. Mitchell Conover
openalex   +1 more source

Perancangan Sistem Informasi Akuntansi Arus Kas Sebagai Pengendali Kas Dengan Metode Accrual Basis Pada CV. Focus Etania Zashika Berbasis Web

, 2023
Ayu Sri Priliyani, Yeny Rostiani, Indaryono Indaryono, Donny Apdian   +3 more
openalex   +2 more sources

Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
This manuscript describes the scope of implementation and impact of a regulatory agency‐qualified panel of six urine biomarkers on drug development, the process for which was conducted and funded by the Critical Path Institute, the Foundation for the National Institutes of Health, and the United States Food and Drug Administration.
Tanja S. Zabka, Michael Lawton, Tom Chu, Gary S. Friedman, Katrina Peron, Stefan R. Sultana, Warren E. Glaab, Nicholas M. P. King   +7 more
wiley   +1 more source

Real and Accrual-Based Earnings Management in the Pre- and Post-Sarbanes Oxley Periods

, 2004
D. Cohen, Aiyesha Dey, Thomas Z Lys
semanticscholar   +1 more source

Corporate Social Responsibility or Strategic Opportunism? Evidence From High and New Technology Firms

Corporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT Corporate Social Responsibility (CSR) presents a dual nature in practice. Beyond its explicit ethical imperatives, it can be strategically instrumentalized to manage external pressures, shape public impression, and even divert attention from corporate misconduct. Acknowledging this complexity, this study investigates the conditions under which
Yang Deng, Assunta Di Vaio, Tze San Ong
wiley   +1 more source

ESG Divergence and Ownership Imbalance: Rethinking Sustainability Value Creation in Mergers and Acquisitions

Corporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT This paper examines how mergers and acquisitions (M&As) affect post‐deal sustainability outcomes by introducing the novel construct of ESG divergence, defined as the distance between acquirer and target firms' pre‐deal ESG profiles. While M&As are increasingly used to accelerate sustainability integration, their ESG impact remains ambiguous ...
Ilaria Galavotti, Donatella Depperu
wiley   +1 more source